Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in ... Business Wire (press release) ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in ... |
